Summary

Marksans Pharma Ltd. reported the financial results for the quarter and nine months ended December 31, 2025. The company delivered a stable and resilient performance in Q3 FY26, with operating revenue growing 10.6% YoY, supported by steady execution across key markets and improved seasonal demand.

Key Highlights

1. 1

   Operating revenue stood at Rs. 754.4 cr., up by 10.6% YoY

2. 2

   Gross profit stood at Rs. 438.2 cr., up by 14.3% YoY

3. 3

   EBITDA stood at Rs. 160.7 cr.; EBITDA margin at 21.3%, expanded 217 bps YoY

4. 4

   US Market: US & North America Formulation business reported revenues of Rs. 412.4 cr. in Q3FY26

5. 5

   UK and Europe Market: Revenues from the UK & Europe Formulation business in Q3FY26 stood at Rs. 258.2 cr.

6. 6

   Australia and New Zealand Market: Australia and New Zealand businesses reported revenues of Rs. 61.4 cr. in Q3FY26

7. 7

   RoW Market: RoW business reported revenues of Rs. 22.4 cr. in Q3FY26

8. 8

   Cash generated from operations at Rs. 263.2 cr. during 9MFY26

9. 9

   Capex of Rs. 97.0 cr. incurred during 9MFY26

10. 10

    Working capital cycle ~151 days for Q3FY26

11. 11

    Cash balance of Rs. 824.2 cr. as on 31 December 2025

12. 12

    Research & development (R&D) spends at Rs. 62.0 cr. in 9MFY26, 3.0% of consolidated revenue